Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Core Insights - Elevation Oncology announced new preclinical data supporting the combination of EO-3021 with VEGFR2 or PD-1 inhibitors, demonstrating enhanced anti-tumor activity [1][2] - The company plans to initiate dosing in the combination portion of its ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 [1][3] Preclinical Data - EO-3021 combined with DC101 (a VEGFR2 inhibitor surrogate) showed tumor growth inhibition (TGI) of 88.2%, significantly higher than 20.1% for EO-3021 alone and 59.2% for DC101 alone [2] - The combination of EO-3021 with a PD-1 inhibitor resulted in a TGI of 79.9%, compared to 33.8% for EO-3021 alone and 25.0% for the PD-1 inhibitor alone [2] - 92% of mice treated with the EO-3021 and PD-1 inhibitor combination achieved a complete response (CR), compared to 50% for EO-3021 monotherapy and 17% for the PD-1 inhibitor alone [2] Clinical Trial Plans - The ongoing Phase 1 clinical trial will evaluate EO-3021 in combination with ramucirumab (a VEGFR2 inhibitor) in the second-line setting and with dostarlimab (a PD-1 inhibitor) in the front-line setting [3][6] - Elevation Oncology continues to enroll patients in the monotherapy dose expansion portion of the trial, with additional data expected in the first half of 2025 [3] Regulatory Designations - EO-3021 received Fast Track designation from the FDA for treating advanced or metastatic gastric/GEJ cancer expressing Claudin 18.2 [7] - The drug also holds orphan drug designation for gastric cancer since November 2020 and for pancreatic cancer since May 2021 [7] Company Overview - Elevation Oncology focuses on developing selective cancer therapies for solid tumors with significant unmet medical needs, leveraging expertise in antibody-drug conjugates (ADCs) [9] - The lead candidate, EO-3021, targets Claudin 18.2 and is currently in a Phase 1 trial for advanced gastric/GEJ adenocarcinoma [9]